Health Canada has approved Mirum Pharmaceuticals’ oral therapy Livmarli (maralixibat) for cholestatic pruritus — that is, itching due…
Articles by Marisa Wexler, MS
An oral tablet formulation of Livmarli (maralixibat) is now approved in Canada to treat pruritus (itching) caused by…
Dosing has begun in a Phase 1/2 clinical trial testing CRMA-1001, Nchroma Bio’s experimental epigenetic therapy being studied as…
Huahui Health‘s Libevitug has become the first approved treatment for chronic hepatitis D virus (HDV) infection in China. The…
People who are exposed to more sunlight over their lifetimes are less likely to develop primary biliary cholangitis (PBC),…
A combination of aerobic exercise and resistance exercise is most effective for reducing liver fat, according to a review of…
After about two years of treatment with the experimental therapies tobevibart and elebsiran, nearly…
Researchers have identified three proteins that may be key targets for treating primary sclerosing cholangitis (PSC), and one of…
A global clinical trial testing Mirum Pharmaceuticals‘ maralixibat for treatment-resistant itching, or pruritus, associated with rare cholestatic conditions…
AX-0810, an experimental treatment for biliary atresia and primary sclerosing cholangitis (PSC), has so far been well tolerated…